3 FTSE Shares You Should Have Bought Last Week: Mulberry Group PLC, Hargreaves Lansdown plc and Hikma Pharmaceuticals Plc

The FTSE 100 (INDEXFTSE:UKX) got trounced this week by Mulberry Group PLC (LON: MUL), Hargreaves Lansdown plc (LON: HL) and Hikma Pharmaceuticals Plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Last week the FTSE 100 (FTSEINDICES: ^FTSE) closed down 185 points, or 2.75%, on the start of the week. Investors were spooked ahead of the referendum in Crimea and economic data indicated a slowdown in China.

If you kept your nerve and bought shares — a great business is still a great business, no matter what market sentiment is — then you might have picked up a bargain or two.

Here are some of the top risers:

Mulberry 

MulberryShares in Mulberry (LSE:  MUL) hiked 5% this week after the chief executive, Bruno Guillon, resigned after serving two years in the role. His tenure had not been successful.

Earlier this year Mulberry’s shares plunged 24% after announcing another profit warning. Guillon stated at the time that the company “continues to invest in the ongoing process of transforming Mulberry from a domestic to a global luxury brand.”

That was his failing. The result of this strategy was a steep hike in prices, that put off consumers. Mulberry has been rudderless for some time after the brand’s creative director, Emma Hill, resigned last summer in opposition to the new direction.

Mulberry’s previous success was based on designs that were expensive, but not out of reach, for many British shoppers. Even in 2009, during the recession, UK sales improved 40%.

Today? Nobody’s buying a Mulberry bag that costs upwards of £1,000. Instead, customers have defected to cheaper brands such as Coach and Michael Kors.

Godfrey Davis, the company’s chairman, will take over until a successor is found.

Hargreaves Lansdown

_ISA2Hargreaves Lansdown (LSE: HL) was a big beneficiary from George Osborne’s Budget announcement on Wednesday. The shares are up 11% since the beginning of the week.

The gains came at the expense of leading insurers, such as Aviva and Legal & General — which fell 11% and 7% respectively — after it was announced that pensioners will no longer require an annuity to remove money from their pension pot.

Hargreaves Lansdown, the UK’s largest investment platform, should receive an upswing in business as pensioners take their savings as a lump sum and invest money in the stock market.

A similarly favourable news snippet was the announcement that ISAs, which currently exist in two forms — cash and stocks — will be merged into a single “New ISA” with a higher annual savings limit of £15,000. Hargreaves sells ISAs, and again, will benefit here.

Hikma Pharmaceuticals

astrazenecaAnalysts were widely predicting Hikma Pharmaceuticals’ (LSE: HIK) final results would show a 90% earnings increase. The shares have been thriving on these expectations.

When the official figures were unveiled they smashed the forecasts, coming in at 111%, and the share price has increased 7% on last week.

Since the beginning of the year Hikma’s gains have more than tripled the leading blue-chip pharma companies GlaxoSmithKline and AstraZeneca combined. Being a smaller company, Hikma Pharmaceuticals is potentially a more attractive growth stock than its larger brethren.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Mark does not own shares in any company mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Stack of one pound coins falling over
Investing Articles

2 penny shares I think could shine in 2025

I have my eye on a few penny shares, as I'm thinking that the year ahead could turn out to…

Read more »

Investing Articles

2 ISA strategies for success in 2025

The ISA is a great vehicle for our investments, sheltering our returns from tax and providing us with the opportunity…

Read more »

Investing Articles

Here’s how an investor could start building a £10,000 second income for £180 per month in 2025

Our writer illustrates how an investor could put under £200 each month into shares and build a long-term five-figure passive…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Here’s how I’m finding bargain shares to buy for 2025!

Our writer takes a fairly simply approach when it comes to hunting for cheap shares to buy for his portfolio.…

Read more »

A graph made of neon tubes in a room
Investing Articles

Up 262%! This lesser-known energy company is putting other S&P 500 stocks to shame

Our writer delves into the rationale behind the parabolic growth of this under-the-radar S&P 500 energy company. The reason isn’t…

Read more »

Investing Articles

Just released: December’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

£20k of savings? Here’s how an investor could turn that into passive income of £5k a year

A £20k lump sum, invested in a mix of blue-chip shares with a long-term approach, could generate thousands of pounds…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is the BP share price set for a 75% jump?

The highest analyst target for BP shares in 2025 is 75% above the current price. So should investors consider buying…

Read more »